Skip Navigation

British Journal of Anaesthesia 2007 98(5):690-691; doi:10.1093/bja/aem076
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pugh, R.
Right arrow Articles by Park, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pugh, R.
Right arrow Articles by Park, G. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage

R. Pugh* and R. Wenstone

Liverpool, UK

* E-mail: pughr@hotmail.com

The first 10% of the full text of this article appears below.

Editor—With the exception of cases of blunt trauma, there is no evidence from randomized controlled trials to support the use of recombinant factor VIIa (rFVIIa) as rescue treatment for severe haemorrhage in non-haemophiliacs. Uncertainty remains regarding what dose of rFVIIa to give, when to give it, how often, and how to optimize its efficacy. Furthermore, a crucial question is: who do you give rFVIIa to and who do you not give . . . [Full Text of this Article]

K. M. Bowles and G. R. Park*

Cambridge, UK

* E-mail: gilbertpark@doctors.org.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?